Klotho Gene Therapy — Gene Therapy & Genetic Interventions
Gene therapy delivering the anti-aging Klotho protein via AAV to restore cognitive function and extend healthspan.
Overview
Klotho is a transmembrane protein and circulating hormone that declines with age and is associated with cognitive decline, kidney disease, and cardiovascular aging. Klotho-deficient mice exhibit accelerated aging, while overexpression extends lifespan by 20-30%. AAV-mediated Klotho gene therapy has shown restoration of cognitive function in aged mice and protection against neurodegeneration. Unity Biotechnology and academic groups are exploring Klotho-based therapies. A single injection of the Klotho protein fragment (KL-F) enhanced cognition in aged primates.
Indications
- Age-related cognitive decline
- Chronic kidney disease progression
- Cardiovascular aging and calcification
- Neurodegenerative disease (preclinical)
- Longevity and healthspan extension
Mechanism of Action
Klotho acts as an obligate co-receptor for FGF23, regulating phosphate homeostasis and vitamin D metabolism
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| AAV-Klotho | 1 x 10^12 - 10^13 vg/kg | Single infusion | Preclinical; dose range from murine/NHP studies |
| Recombinant KL-F protein | 10 mcg/kg | Single injection | Acute cognitive enhancement shown in NHP studies |
Evidence Grade
GRADE D
Safety & Contraindications
- Klotho overexpression effects on mineral metabolism (phosphate, vitamin D) require monitoring
- AAV vector immunogenicity concerns
- Potential for FGF23-Klotho axis disruption affecting calcium/phosphate homeostasis
- No human clinical trial data for gene therapy delivery
- Recombinant protein delivery may have different risk profile than gene therapy